Drugs / BMS-986310
Trials 8 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 16 trials | ||||||
| Phase 1 | NCT06570031 | Nov 2021 → Apr 2026 | hormone receptor-positive breast cancer | Ono Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT06542731 | Jun 2021 → Sep 2026 expected | non-small cell lung carcinoma | Ono Pharmaceutical Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 1 | NCT06547385 | Jan 2021 → Oct 2027 expected | colorectal cancer | Ono Pharmaceutical Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 1 | NCT06538207 | Jan 2021 → Oct 2024 | malignant pancreatic neoplasm | Ono Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT03661632 | Sep 2018 → Nov 2019 | cancer of unknown primary site | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT03155061 | Apr 2017 → Mar 2027 expected | — | Ono Pharmaceutical Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT06948448 | Nov 2025 → Feb 2028 expected | colorectal cancer | Ono Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT06256328 | Jan 2024 → Oct 2025 overdue | gastric cancer | Ono Pharmaceutical Co., Ltd. | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BMS-986310 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03661632 ↗ |
| Known as | ONO-4578 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06542731 ↗ |
| Action | Inhibit | “ONO-4578, a highly selective EP4 antagonist” PMID 36082616 ↗ Nov 2022 |
| Modality | Small molecule | — CHEMBL5314911 ↗ |